New organization offers support to contract research organizations and contract manufacturing organizations in the New England area.
The New England CRO/CMO Council, a new resource for the biotech and pharmaceutical community in and around Boston, held its inaugural members meeting in early December 2014. The non-profit council was established to market the Boston-area CRO/CMO market and will work with life-science government agencies and trade organizations to promote local outsourcing. Nearly 30 local CROs/CMOs as well as industry consultants attended the council’s inaugural meeting on Dec. 10, 2014.
"More than 75 CROs and CMOs operate within two and a half hours of Boston, making this region the largest cluster of its kind. We represent every phase of outsourcing, which provides another reason this region is ideal for drug development," said Edward Price, president of PCI Synthesis, a sponsor and steering committee member of the New England CRO/CMO Council, in a press release. "We started the N.E. CRO/CMO Council to give a voice to local companies working to raise awareness in the larger community and in other regions. Given that it takes longer and costs more to develop drugs, the council is also looking at ways its members can streamline processes, collaborate more effectively, and help our clients get their drugs ready for FDA approval and then to manufacture those drugs on a large scale-basis."
Ushering in Industry 4.0 with the IDMO Model to Solve the CGT Manufacturing Bottleneck
May 28th 2025Global scale-up requires developing replicable processes that work the same no matter where they are performed. This can be accomplished with smart factories that utilize fully automated manufacturing platforms.
Novel Modalities Spur Shift in Outsourcing Processes and Partnerships
May 8th 2025While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as transactional relationships, but true partners with a common goal of getting drugs to patients faster.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.